REMARKS

Claims 1-6, 8-9, 12-13, 15-18, 20-23, 31-32, 34-37, and 50 are pending in this application.

Claim 7 is cancelled in this paper without prejudice to Applicant's right to pursue the subject matter recited by it in one or more divisional, continuation, or continuation-in-part applications.

Claim 1 has been amended; support for this amended claim can be found throughout United States Patent Application Publication No. 2004/0171147 A1 (hereinafter "the present application") at, for example, paragraphs [0011]-[0013] and [0019]-[0022] and [0039] and [0043].

Claim 18 has been amended; support for this amended claim can be found throughout the present application at, for example, paragraphs [0039] and [0043] and [0047] and [0050] and [0060]-[0062].

Claim 31 has been amended; support for this amended claim can be found throughout the present application at, for example, paragraph [0018] and [0039] and [0043] and [0047] and [0050] and [0060]-[0062].

Claim 34 has been amended; support for this amended claim can be found throughout the present application at, for example, paragraphs [0019] and [0039] and [0043].

Claim 50 has been amended; support for this amended claim can be found throughout the present application at, for example, [0011]-[0013], [0019]-[0022], [0039], [0042]-[0043], [0060]-[0062], and original claim 50.

No new matter has been added.

Interview Summary

Applicant's representative (Richard T. Girards, Jr.) thanks the Examiner and Primary Examiner for the courtesies extended during the Interview.

The parties discussed certain pending claims. The parties agreed that limited amendments would render all claims suitable for immediate allowance. Specifically, for example, pursuant to suggestions of the Examiners, Applicant's representative agreed to add limitations into claims with respect to cell numbers, consistent with certain embodiments of the invention supported by the specification at, for example, paragraph [0039]. Applicant's representative further agreed, pursuant to suggestions

of the Examiners, to delete claim 7. Finally, Applicant's representative agreed to amend the claims to clarify that, in certain presently claimed embodiments of the invention, a placenta from which cells may be obtained is a postpartum placenta.

Applicant's representative and Examiners discussed the possibility that divisional and continuation applications would be filed by Applicant to claim other embodiments of the invention.

In light of the Interview and the claims amendments introduced herein,
Applicant's representative respectfully requests that the Examiner allow the pending
claims as soon as reasonably possible. Should there by any further matters requiring
consideration, the Examiner is invited to contact the undersigned counsel.

Respectfully submitted,

DATE: 05 April 2006

Richard T. Girards, Jr. Reg. No. 52,946

Celgene Corporation 86 Morris Avenue Summit, NJ 07901 (908) 673-9543 (phone) (908) 673-2771 (facsimile)